Product information and disease descriptionPlace of product in therapyApproaches to treatmentCurrent treatment options and standard of care
Nonsteroidal immunosuppressive agents
3 evidence topics · 3 sources
Indications for and choice of nonsteroidal immunosuppressive agents: international consensus guidance
“A nonsteroidal IS agent should be used alone when corticosteroids are contraindicated or refused. A nonsteroidal IS agent should be used initially in conjunction with corticosteroids when the risk of steroid side effects is high based on medical comorbidities. A nonsteroidal IS agent should be added to corticosteroids when: a. Steroid side effects, deemed significant by the patient or the treating physician, develop; b. Response to an adequate trial (table e-1) of corticosteroids is inadequate; or c. The corticosteroid dose cannot be reduced due to symptom relapse.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Nonsteroidal IS agents that can be used in MG include azathioprine, cyclosporine, mycophenolate mofetil, methotrexate, and tacrolimus. The following factors should be considered in selecting among these agents: a. There is widespread variation in practice with respect to choice of IS agent since there is little literature comparing them. b. Expert consensus and some RCT evidence support the use of azathioprine as a first-line IS agent in MG. c. Evidence from RCTs supports the use of cyclosporine in MG, but potential serious adverse effects and drug interactions limit its use. d. Although available RCT evidence does not support the use of mycophenolate and tacrolimus in MG, both are widely used, and one or both are recommended in several national MG treatment guidelines” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“For nonsteroidal IS agents, once treatment goals have been achieved and maintained for 6 months to 2 years, the IS dose should be tapered slowly to the minimal effective amount.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Methotrexate as a steroid-sparing agent: 2020 consensus update
“An RCT enrolled 50 patients with AChR-Ab+ MG taking prednisone at a dose of ≥10 mg/d. 34 Patients were randomized 1:1 to MTX 20 mg/wk or placebo. There was no difference in the primary outcome measure, the area under the prednisone dose-time curve between months 4 and 12, and the mean 12-month change in QMG, MMT, MG-Quality of life, MG-ADL, and MGC was no different between treatment groups.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Although evidence from RCTs is lacking, oral MTX may be considered as a steroid-sparing agent in patients with generalized MG who have not tolerated or responded to steroid-sparing agents that are better supported by RCT data” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Azathioprine first choice and onset of effect: Nordic guidance
“These drugs have a delayed response of 1 to 6 months, and the full effect is sometimes reached after more than 1 year.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“In the Nordic countries, azathioprine (2–3 mg/kg) is usually the first‐line treatment in both adults and children. Mycophenolate (1–2 g daily), methotrexate (20 mg/week), and tacrolimus (3 mg daily) are secondary alternatives.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Azathioprine is recommended as the first‐choice non‐steroidal immunosuppressant drug. Mycophenolate, methotrexate, and tacrolimus are recommended as secondary immunosuppressants.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote